Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study

@inproceedings{Fadini2018UseAE,
  title={Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study},
  author={Gian Paolo Fadini and Giancarlo Zatti and Ileana Baldi and Daniele Bottigliengo and Agostino Consoli and Andrea Giaccari and Giorgio Sesti and Angelo Avogaro},
  booktitle={Diabetes, obesity & metabolism},
  year={2018}
}
In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Dapagliflozin: A Review in Type 2 Diabetes

VIEW 17 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

G. P. Fadini, P. Li Volsi, +4 authors A. Avogaro
  • Journal of Endocrinological Investigation
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.

  • Journal of the American Society of Hypertension : JASH
  • 2014
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL